𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Identifying the types of missingness in quality of life data from clinical trials

✍ Scribed by D. Curran; M. Bacchi; S. F. Hsu Schmitz; G. Molenberghs; R. J. Sylvester


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
268 KB
Volume
17
Category
Article
ISSN
0277-6715

No coin nor oath required. For personal study only.

✦ Synopsis


This paper discusses methods of identifying the types of missingness in quality of life (QOL) data in cancer clinical trials. The first approach involves collecting information on why the QOL questionnaires were not completed. Based on the reasons provided one may be able to distinguish the mechanisms causing missing data. The second approach is to model the missing data mechanism and perform hypothesis testing to determine the missing data processes. Two methods of testing if missing data are missing completely at random (MCAR) are presented and applied to incomplete longitudinal QOL data obtained from international multi-centre cancer clinical trials. The first method (Ridout, 1991) is based on a logistic regression and the second method (Park and Davis, 1993) is based on an adaptation of weighted least squares. In one application (advanced breast cancer) missing data was not likely to be MCAR. In the second application (adjuvant breast cancer) the missing mechanism was dependent on the QOL scale under study. MCAR and missing at random (MAR) have distinct consequences for data analysis. Therefore it is relevant to distinguish between them. However, if either MCAR or MAR hold, likelihood or Bayesian inferences can be based solely on the observed data, although for MAR, depending on the research question, modelling the dropout mechanism may still be necessary. Distinguishing between MAR and missing not at random (MNAR) is not trivial and relies on fundamentally untestable assumptions.


πŸ“œ SIMILAR VOLUMES


Suggestions for the presentation of qual
✍ David Machin; Simon Weeden πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 237 KB πŸ‘ 2 views

Quality of life (QOL) data is complex since it is both multidimensional and longitudinal. This complexity is compounded with its unbalanced nature through missing observations as a consequence of patient non-compliance with assessment schedules, and, for example, in cancer clinical trials data absen

Statistical analysis of quality of life
✍ Andrea B. Troxel; Diane L. Fairclough; Desmond Curran; Elizabeth A. Hahn πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 255 KB πŸ‘ 2 views

We summarize issues that arise when considering quality of life (QOL) data in cancer clinical trials, especially those related to missing data. We describe different types of missing data mechanisms, and discuss ways of assessing and testing missing data mechanisms. A section on presentation of stud

Item response models for longitudinal qu
✍ Jeffrey A. Douglas πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 140 KB πŸ‘ 2 views

Assessment of quality of life is becoming standard in clinical trials. A popular method for measuring quality of life is with instruments which utilize multiple-item subscales, in which each item is scored on a Likert scale. Most statistical methods for the analysis of quality of life data in clinic

Missing quality of life data in cancer c
✍ JΓΌrg Bernhard; David F. Cella; Alan S. Coates; Lesley Fallowfield; Patricia A. G πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 173 KB πŸ‘ 2 views

Measurement of quality of life (QOL) in cancer clinical trials has increased in recent years as more groups realize the importance of such endpoints. A key problem has been missing data. Some QOL data may unavoidably be missing, as for example when patients are too ill to complete forms. Other impor

Why are missing quality of life data a p
✍ Diane L. Fairclough; Harriet F. Peterson; Victor Chang πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 116 KB πŸ‘ 2 views

Assessment of health related quality of life has become an important endpoint in many cancer clinical trials. Because the participants of these trials often experience disease and treatment related morbidity and mortality, non-random missing assessments are inevitable. Examples are presented from se